dddaeeca

Daniel Collins

Contact us by Email

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Daniel Collins

  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///HIV
    Company & Industry Overviews

    Could Gilead Sciences’ Biktarvy Witness Solid Growth in 2018?

    In February 2018, the US FDA approved Gilead Sciences’ Biktarvy for the treatment of individuals with HIV-1 infection.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Merck in September

    Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Taltz
    Company & Industry Overviews

    Eli Lilly’s Immunology Business Saw Solid Growth in 2017

    In 4Q17, Eli Lilly’s (LLY) Taltz generated revenues of $172.5 million compared to $61.3 million in 4Q16.

    By Daniel Collins
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Tysabri revenues
    Earnings Report

    How 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta

    Tysabri revenue trends In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 […]

    By Daniel Collins
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///Vaccine Franchise
    Company & Industry Overviews

    How Merck’s Vaccines Business Is Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///cure _
    Company & Industry Overviews

    A Performance Overview of Johnson & Johnson

    Johnson & Johnson, which reported its third-quarter earnings results on October 16, generated net revenue of $20.3 billion in the quarter.

    By Daniel Collins
  • uploads///CNTTF
    Company & Industry Overviews

    CannTrust Holdings’ Stock Grew ~11% Last Week

    On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

    By Daniel Collins
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///featured image
    Company & Industry Overviews

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.

    By Daniel Collins
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Humira Revenues
    Company & Industry Overviews

    Humira May Continue to Drive AbbVie’s Revenue Growth

    In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

    By Daniel Collins
  • uploads///Diabetes
    Company & Industry Overviews

    Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17

    In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///Virology
    Company & Industry Overviews

    How Merck’s Zepatier and Isentress Are Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.

    By Daniel Collins
  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///otc_and_api
    Company & Industry Overviews

    Teva Pharmaceutical’s Generic Medicines Segment in 4Q17

    In 4Q17, Teva Pharmaceutical’s (TEVA) generic medicines segment reported revenues of $3.1 billion compared to $3.7 billion in 4Q16.

    By Daniel Collins
  • uploads///Immunology Oncology
    Company & Industry Overviews

    A Look into Merck’s Immunology and Oncology Portfolio

    In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

    By Daniel Collins
  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///Saxendra
    Company & Industry Overviews

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY growth.

    By Daniel Collins
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///Eylea
    Company & Industry Overviews

    Eylea Could Continue to Generate High Revenue

    Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.

    By Daniel Collins
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Noxafil and Cubicin
    Company & Industry Overviews

    Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin

    In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///nerve cell _
    Company & Industry Overviews

    Aptinyx Stock Plunged 70% after Clinical Trial Failure

    Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.

    By Daniel Collins
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts Recommendations for AbbVie in August 2017

    Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

    By Daniel Collins
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///Humira revenues
    Company & Industry Overviews

    AbbVie’s Humira Continues to Generate High Revenues

    In 2Q17, AbbVie’s (ABBV) Humira generated revenues of $4.7 billion, which was a 14.0% rise YoY (year-over-year) and a 15.0% rise QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Merck Performance
    Company & Industry Overviews

    How Merck Is Expected to Perform in 2017

    In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.

    By Daniel Collins
  • uploads///Vaccine revenues
    Company & Industry Overviews

    How Pfizer’s Vaccine Franchise Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///microbiology Picture
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive about Johnson & Johnson

    In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///cannabis _
    Company & Industry Overviews

    Marijuana Stock iAnthus Capital Already Up ~23% in January

    Today, on the OTC markets, iAnthus Capital Holdings stock (ITHUF) is trading ~3.63% above yesterday’s closing price of $4.84.

    By Daniel Collins
  • uploads///CWBHF
    Company & Industry Overviews

    Charlotte’s Web Holdings’ Stock Grew ~11% Last Week

    On January 25, Charlotte’s Web Holdings’ (CWBHF) stock price closed at $14.41, ~4.87% higher than its closing price of $13.74 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%

    Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.

    By Daniel Collins
  • uploads///green _
    Company & Industry Overviews

    Which Cannabis Stocks Were in the Green on January 24?

    On January 24, Cannabis Strategic Ventures stock closed at $1.69—an ~8.33% rise compared to its closing price of $203.66 on January 23.

    By Daniel Collins
  • uploads///capsule _
    Earnings Report

    Johnson & Johnson Releases Its 2018 Results: Revenue Up 6.7%

    Today, Johnson & Johnson (JNJ) released its fourth-quarter and 2018 financial results.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    Boston Scientific and Edward Lifesciences Settle Patent Dispute

    Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.

    By Daniel Collins
  • uploads///GTI
    Company & Industry Overviews

    How Is Green Thumb Industries Financially Positioned in January?

    Green Thumb Industries reported net revenue of $17.17 million in the third quarter of 2018. What do analysts expect for the fourth quarter?

    By Daniel Collins
  • uploads///GTI Oppor
    Company & Industry Overviews

    GTBIF Acquires Advanced Grow Labs and Enters Connecticut Market

    In January, Green Thumb announced that it had entered into a definitive agreement to acquire Advanced Grow Labs for a value of $80.0 million.

    By Daniel Collins
  • uploads///Insys therap
    Company & Industry Overviews

    How INSYS Therapeutics’ Earnings Were Trending

    In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively.

    By Daniel Collins
  • uploads///INSY
    Company & Industry Overviews

    How Is INSYS Therapeutics Financially Positioned in January?

    In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

    By Daniel Collins
  • uploads///flowers _
    Company & Industry Overviews

    Cannabis Stock INSYS Therapeutics Has Risen 28% in January

    On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.

    By Daniel Collins
  • uploads///GW Oppor
    Company & Industry Overviews

    Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

    GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.

    By Daniel Collins
  • uploads///GWPH Net loss
    Company & Industry Overviews

    How GW Pharmaceuticals’ Earnings Are Trending

    In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.

    By Daniel Collins
  • uploads///GW revenue
    Company & Industry Overviews

    A Look into GW Pharmaceuticals’ Revenue Trends

    In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

    By Daniel Collins
  • uploads///herb _
    Company & Industry Overviews

    GW Pharmaceuticals Has Already Soared 23% in January

    GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.

    By Daniel Collins
  • uploads///microbiology _
    Company & Industry Overviews

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday

    On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.

    By Daniel Collins
  • uploads///brain _
    Company & Industry Overviews

    Why Neurocrine Biosciences Stock Rose 9.6% Yesterday

    On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.

    By Daniel Collins
  • uploads///SRPT EPS
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Recent Developments

    In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    How Is Sarepta Therapeutics Positioned in January?

    In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Sarepta Therapeutics Stock Rose 96% in 2018

    On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

    By Daniel Collins
  • uploads///sw
    Company & Industry Overviews

    Why Portola Pharmaceuticals Rose 8.09% on January 4

    On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,

    By Daniel Collins
  • uploads///BMYcelgene
    Company & Industry Overviews

    What to Expect from BMY’s Celgene Acquisition

    The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Bristol-Myers Squibb to Acquire Celgene

    Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

    By Daniel Collins
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Diabetes Care Stock Soared Over 1,480% in 2018

    Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.

    By Daniel Collins
  • uploads///Spectrum net loss
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

    By Daniel Collins
  • uploads///Teva pharma
    Company & Industry Overviews

    A Financial Overview of Teva Pharmaceutical in December

    In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Teva Pharmaceutical Stock Rose More than ~8% on December 26

    On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

    By Daniel Collins
  • uploads///Vaccines
    Company & Industry Overviews

    Pfizer’s Vaccines: A Look at Their Market Performance

    In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

    By Daniel Collins
  • uploads///Xtandi
    Company & Industry Overviews

    Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

    In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    How Pfizer’s Sutent and Xalkori Have Performed

    In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

    By Daniel Collins
  • uploads///Untitled
    Company & Industry Overviews

    Pfizer and GlaxoSmithKline’s Joint Venture: What to Expect

    The new joint venture between GlaxoSmithKline and Pfizer will enable GlaxoSmithKline to strengthen its consumer healthcare business.

    By Daniel Collins
  • uploads///PFE con
    Company & Industry Overviews

    Pfizer and GlaxoSmithKline’s Consumer Health Business

    Pfizer’s (PFE) consumer health business generated revenues of $2.6 billion during the first nine months in 2018.

    By Daniel Collins
  • uploads///toothbrush _
    Company & Industry Overviews

    Pfizer and GlaxoSmithKline Form a Joint Venture

    On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.

    By Daniel Collins
  • uploads///PFE income
    Company & Industry Overviews

    Pfizer’s Stock Performance and Earnings Trends

    On December 17, Pfizer’s stock price closed at $43.11, which is an ~1.58% decline from its close of $43.80 on December 14.

    By Daniel Collins
  • uploads///PFE
    Company & Industry Overviews

    Analyzing Pfizer’s Revenues in December

    Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.

    By Daniel Collins
  • uploads///MDT RTG
    Company & Industry Overviews

    How Did Medtronic’s Restorative Therapies Group Perform?

    Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.

    By Daniel Collins
  • uploads///MITG
    Company & Industry Overviews

    How Medtronic’s Minimally Invasive Therapies Group Has Performed

    Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.

    By Daniel Collins
  • uploads///MDTs CVG
    Company & Industry Overviews

    A Look at Medtronic’s Cardiac & Vascular Group’s Revenue Streams

    Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019.

    By Daniel Collins
  • uploads///MDT net income
    Company & Industry Overviews

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.

    By Daniel Collins
  • uploads///RTG
    Company & Industry Overviews

    How Does Medtronic’s Restorative Therapies & Diabetes Group Look?

    Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty and Pain therapies.

    By Daniel Collins
  • uploads///analysis _
    Company & Industry Overviews

    How Wall Street Analysts View Medtronic in December

    Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

    By Daniel Collins
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///flasks _
    Company & Industry Overviews

    Why Exelixis Stock Soared 46% in November

    Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

    By Daniel Collins
  • uploads///human skeleton _
    Company & Industry Overviews

    United Health Group Stock Has Risen 28% in 2018

    On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23.

    By Daniel Collins
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///BSX
    Company & Industry Overviews

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.

    By Daniel Collins
  • uploads///ISRG
    Company & Industry Overviews

    Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date

    Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Endocyte Stock Has Seen a Solid Hike in 2018

    Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018.

    By Daniel Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.